13 results about "Retinol binding protein" patented technology

The invention discloses a retinol binding protein detection kit and a preparation method thereof. The detection kit comprises a reagent R1 and a reagent R2. The reagent R1 comprises an oxidizing agent and is beneficial to maintaining the structural stability of the retinol binding protein. And the R2 reagent comprises latex microspheres loaded with a retinol binding protein antibody. According to the present invention, the antibody directional coupling technology is adopted, such that the stable thioether bond is formed between the retinol binding protein antibody and the latex microsphere, the retinol binding protein antibody is coupled to the latex microsphere, the antibody is connected with the microsphere through the Fc region, and the Fab region extends outward so as not to affect the antibody active region configuration, and the efficient combination with the sample antigen is achieved;

Compositions and methods use one or more feline circulating proteins as markers for early chronic kidney disease (CKD) to diagnose and / or treat CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), antibacterial peptide (CAMP), kinetin-like protein (KIF12), plasma retinol binding protein (RBP4), Ig-like domain containing protein (ZKSCAN1), blood coagulation factor X (F10), fibronectin (FN1), and mixtures thereof. The method further comprises comparing the amount of each of the at least one circulating protein from the feline to a respective predetermined value or a respective predetermined range. The method further comprises diagnosing the feline as having or not having early CKD based on the comparison.

The invention relates to the technical field of medical examination, in particular to a stable compound type special protein control product and a preparation method thereof.The preparation method comprises the steps that purified water is taken, a buffer solution, a protective agent, a first stabilizer, a chelating agent, C-reactive protein, antistreptolysin O, rheumatoid factors and retinol binding protein are sequentially added, the mixture is fully stirred till being completely dissolved, and the stable compound type special protein control product is obtained; putting into a constant-temperature box for aging to obtain a dissolving solution; taking out the dissolved solution, standing to room temperature, and filtering by using a peristaltic pump and a bag type filter to obtain a filtrate; and sequentially adding a second stabilizer, cystatin C protein, a third stabilizer, an ion balance agent, lipoprotein (a) and a preservative into the filtrate, and adjusting the pH value to obtain the composite special protein control product. The method can be used for quality control of biochemical item detection processes of retinol binding protein, cystatin C protein, C-reactive protein, antistreptolysin 'O', rheumatoid factors and lipoprotein (a) at the same time.

The application provides a liquid chromatography analysis method for simultaneously detecting multiple proteins, which adopts anion liquid chromatography with non-porous resin as a stationary phase, a Tris gradient eluent phase containing Cl ‑ , the non-porous resin is bonded with a hydrophilic polymer nanolayer on the surface, the nanolayer is modified with a quaternary ammonium group, the proteins have different isoelectric points, and the pH of the eluent phase is greater than the isoelectric points of the proteins. The application can simultaneously separate and purify multiple proteins through one-time anion liquid chromatography, and can approximately achieve baseline separation. The overall method is simple, economical, efficient, and environmentally friendly for the mobile phase, and is suitable for the separation of proteins with different isoelectric points, and is particularly suitable for the detection and separation of proteins such as albumin, transferrin, retinol binding protein, beta 2 microglobulin and alpha 1 microglobulin in urine.

The present invention relates to a method for selecting a patient suffering from a stroke for reperfusion therapy, based on determining the levels of retinol binding protein 4 (RBP4) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The present invention also relates to a method for differentiating between ischemic stroke and hemorrhagic stroke, and to a kit comprising reagents for performing said methods.

Based on co-drugs representing two different chemical entities, and the co-administration and sequential administration of said two chemical entities, novel therapies are provided for macular degeneration, non-alcoholic fatty liver disease (NAFLD), and gouty arthritis (gout). The first component (“Selective RBP4 Antagonist”) is a chemical entity that interacts with RBP4 (retinol-binding protein 4), part of the RBP4-TTR (transthyretin) complex that delivers retinol to the retina. This component reduces the transport of retinol from circulation to the retina. The second component (“C20-D3-Visual Chromosome-Generating Compound”) is a C20-D3-modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore in the retina representing either C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at the C20 position reduces the formation of lipofuscin biretinol, while other functions (such as providing a precursor for the in vivo synthesis of visual chromophore 11-cis-retinaldehyde) are not reduced.

To provide a method of selecting a patient suffering stroke for a reperfusion therapy, a method of differentiating ischemic stroke from hemorrhagic stroke, and to kits comprising reagents for implementing the methods.SOLUTION: A method of selecting a patient suffering stroke for a reperfusion therapy is provided, the method comprising determining the level of retinol-binding protein-4 (RBP4) and the level of N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of a patient. The method further comprises determining the level of glial fibrillary acid protein (GFAP) in the isolated sample.SELECTED DRAWING: Figure 3

The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.

The utility model relates to the technical field of incubators, and provides a retinol binding protein incubator which comprises an incubator body, a motor and a fixing support are fixedly installed at the bottom of the incubator body respectively, the motor is located on the inner side of the fixing support, a rotating rod is rotatably installed on the inner bottom wall of the incubator body, and the output end of the motor is fixedly connected with the rotating rod. A plurality of T-shaped discs are sequentially arranged on the outer side wall of a rotating rod from top to bottom, the rotating rod is driven by a motor to rotate, and then the rotating rotating rod drives the T-shaped discs to rotate under the cooperation of a locking assembly and an inserting hole, so that a culture dish to be taken can be moved to the right front, personnel can take the culture dish conveniently, and the working efficiency is improved. Furthermore, all the culture dishes do not need to be taken out from the box body, the influence on other culture dishes can be reduced, and meanwhile, when the motor drives the T-shaped disc to rotate, objects in the culture dishes shake under the action of centrifugal force, so that nutrient substances in a culture solution can be ensured to be uniformly distributed, and the growth and metabolic activity of cells are promoted.

To provide compositions for effective treatment of retinol binding protein 4 (RBP4)-related visual diseases and disorders.SOLUTION: A pharmaceutical composition comprising (i) a compound of formula (I), or a pharmaceutically acceptable salt, crystal, solvate, polymorph, prodrug, metabolite, N-oxide, stereoisomer, or isomer thereof, and (ii) a dispersion polymer.SELECTED DRAWING: Figure 2

The application provides a reagent for detecting RBP1 for preparing a kit for diagnosing atrial fibrillation, difference genes of atrial fibrillation patients and non-atrial fibrillation patients are obtained through weight gene co-expression network analysis (WGCNA), and RT-qPCR is used for verification in human peripheral blood samples. Peripheral blood leukocyte extraction: 3-5ml of venous blood is taken, EDTA anticoagulation is carried out, and centrifugation is carried out at 2500rpm for 10min; the upper plasma is carefully sucked and is divided into 3 0.5ml centrifuge tubes; 3 times the volume of hemolytic liquid is added into the blood cells, and shaking is carried out, ice bath is carried out for 15min; 2500rpm centrifugation is carried out for 10min, and the supernatant is discarded. The RBP1 detection method can be used as a biomarker to assist the diagnosis of atrial fibrillation. Retinol binding protein 1 is a protein encoded by the CRABP1 gene. It binds with high affinity to retinol and retinoids, protects retinoids from nonspecific oxidation, and delivers retinoids to specific enzymes. Changes in RBP1 gene expression will affect retinoic acid production, cell proliferation and microenvironment of epithelial cells. Blood biomarker sampling is simple and low in price.

The application provides an analysis method for simultaneously detecting multiple proteins in urine, which sequentially filters the urine through a hydrophilic MCE filter membrane, a volume exclusion gel column containing dextran, and a high performance anion exchange chromatography column containing a non-porous resin filler with a functional group of + (CH3)3, to remove impurities and concentrate target proteins, and then uses high performance anion exchange chromatography of the non-porous resin filler with a functional group of + (CH3)3 to perform detection analysis. The method is simple in operation and few in steps, and can quickly and accurately perform qualitative and quantitative analysis on proteins such as albumin, transferrin, retinol binding protein, beta 2 microglobulin and alpha 1 microglobulin in urine.

The invention belongs to the technical field of biology, and particularly relates to a method for improving the in-vitro maturation quality of ovum and the blastocyst quality and application of the ovum and blastocyst quality. The invention discloses beta-sodium glycerophosphate pentahydrate. According to the preparation, at least one of the retinol binding protein and the sodium beta-glycerophosphate pentahydrate is added to improve the cleavage rate and blastocyst rate of an in-vitro embryo, the oxidation resistance of an oocyte and the like, so that the maturation quality of the in-vitro oocyte and the development potential of the in-vitro embryo are remarkably improved, and the application prospect is wide.